#ECTRIMS2021 – Lower Relapse Rates Seen With Tysabri Than Ocrevus

#ECTRIMS2021 – Lower Relapse Rates Seen With Tysabri Than Ocrevus

309249

#ECTRIMS2021 – Lower Relapse Rates Seen With Tysabri Than Ocrevus

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference. People with multiple sclerosis (MS) treated with Tysabri (natalizumab) are less likely to experience disease relapses than those given Ocrevus (ocrelizumab), according to an analysis of real-world insurance data. Data from a Phase 3b clinical trial also…

You must be logged in to read/download the full post.